Page 1076 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

125. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of Diseases Mycoses Study Group and AIDS Clinical Trials Group.
liposomal amphotericin B compared with conventional ampho- N Engl J Med. 1997;337:15-21.
tericin B for induction therapy of histoplasmosis in patients 143. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination
with AIDS. Ann Intern Med. 2002;137:105-109. antifungal therapies for HIV-associated cryptococcal meningi-
126. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment tis: a randomised trial. Lancet. 2004;363:1764-1767.
of disseminated histoplasmosis in patients with the acquired 144. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early
immunodeficiency syndrome. AIDS Clinical Trial Group. Am J fungicidal activity of high-dose fluconazole, voriconazole, and
Med. 1995;98:336-342. flucytosine as second-line drugs given in combination with
127. Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis amphotericin B for the treatment of HIV-associated cryptococ-
during human immunodeficiency virus infection: a review of cal meningitis. Clin Infect Dis. 2012;54:121-128.
77 patients. Medicine (Baltimore). 1990;69:384-391. 145. Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses
128. Jones JL, Fleming PL, Ciesielski CA, Hu DJ, Kaplan JE, Ward of liposomal amphotericin B and conventional amphotericin
JW. Coccidioidomycosis among persons with AIDS in the B deoxycholate for treatment of AIDS-associated acute crypto-
United States. J Infect Dis. 1995;171:961-966. coccal meningitis: a randomized, double-blind clinical trial of
efficacy and safety. Clin Infect Dis. 2010;51:225-232.
129. Galgiani JN, Ampel NM. Coccidioidomycosis in human
immunodeficiency virus-infected patients. J Infect Dis. 146. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined
1990;162:1165-1169. with flucytosine for treatment of cryptococcal meningitis in
patients with AIDS. Clin Infect Dis. 1994;19:741-745.
130. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis.
Clin Infect Dis. 2005;41:1217-1223. 147. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early
fungicidal activity, and outcome in cryptococcal meningitis
131. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy in antiretroviral-naive or antiretroviral-experienced patients
for coccidioidal meningitis. The NIAID-Mycoses Study Group. treated with amphotericin B or fluconazole. Clin Infect Dis.
Ann Intern Med. 1993;119:28-35. 2007;45:76-80.
132. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole 148. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cere-
therapy for chronic coccidioidal meningitis. Ann Intern Med. brospinal fluid pressure, fungal burden and outcome in patients
1990;112:108-112. with cryptococcal meningitis undergoing serial lumbar punc-
133. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to tures. AIDS. 2009;23:701-706.
stop azole therapy for Coccidioides immitis meningitis? Ann 149. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of
Intern Med. 1996;124:305-310. maintenance therapy for cryptococcal meningitis in patients
134. Huang L, Schnapp LM, Gruden JF, Hopewell PC, Stansell JD. with AIDS treated with highly active antiretroviral therapy:
Presentation of AIDS-related pulmonary Kaposi’s sarcoma an international observational study. Clin Infect Dis. 2004;38:
diagnosed by bronchoscopy. Am J Respir Crit Care Med. 565-571.
1996;153:1385-1390. 150. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice
135. Aboulafia DM. The epidemiologic, pathologic, and clinical fea- guidelines for the management of cryptococcal disease: 2010
tures of AIDS-associated pulmonary Kaposi’s sarcoma. Chest. update by the infectious diseases society of america. Clin Infect
2000;117:1128-1145. Dis. 2010;50:291-322.
136. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly 151. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement
active antiretroviral therapy on survival in patients with AIDS- of cryptococcal antigen in serum and cerebrospinal fluid: value
associated pulmonary Kaposi’s sarcoma treated with chemo- in the management of AIDS-associated cryptococcal meningi-
therapy. J Clin Oncol. 2001;19:3848-3851. tis. Clin Infect Dis. 1994;18:789-792.
137. Palmieri C, Dhillon T, Thirlwell C, et al. Pulmonary Kaposi 152. Antinori A, Larussa D, Cingolani A, et al. Prevalence, associated
sarcoma in the era of highly active antiretroviral therapy. HIV factors, and prognostic determinants of AIDS-related toxoplas-
Med. 2006;7:291-293. mic encephalitis in the era of advanced highly active antiretro-
viral therapy. Clin Infect Dis. 2004;39:1681-1691.
138. Price, RW. Neurological disease. In: Dolin R, Masur H, Saag M,
eds. AIDS Therapy. 2nd ed. New York: Churchill Livingstone; 153. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemi-
2003:737. ology and survival of progressive multifocal leukoencepha-
lopathy in the era of highly active antiretroviral therapy: data
139. Antinori A, Arendt G, Becker JT, et al. Updated research nosol- from the Italian Registry Investigative Neuro AIDS (IRINA).
ogy for HIV-associated neurocognitive disorders. Neurology. J Neurovirol. 2003;9(suppl 1):47-53.
2007;69:1789-1799.
154. De Luca A, Ammassari A, Pezzotti P, et al. Cidofovir in addition
140. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis to antiretroviral treatment is not effective for AIDS-associated
in patients infected with the human immunodeficiency virus. progressive multifocal leukoencephalopathy: a multicohort
N Engl J Med. 1992;326:668-672. analysis. AIDS. 2008;22:1759-1767.
141. Scarpellini P, Racca S, Cinque P, et al. Nested polymerase 155. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of
chain reaction for diagnosis and monitoring treatment human immunodeficiency virus type 1 RNA in cerebrospi-
response in AIDS patients with tuberculous meningitis. AIDS. nal fluid correlate with AIDS dementia stage. J Infect Dis.
1995;9:895-900. 1997;175:963-966.
142. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryp- 156. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing
tococcal meningitis associated with the acquired immunodefi- antiretroviral therapy for human immunodeficiency virus cog-
ciency syndrome. National Institute of Allergy and Infectious nitive disorders. Ann Neurol. 2004;56:416-423.

Section05-O-ref.indd 5 1/20/2015 4:51:22 PM